Literature DB >> 15186301

Impact of headache on quality of life in a general population survey in France (GRIM2000 Study).

Gérard Duru1, Jean-Paul Auray, Anne-Françoise Gaudin, Jean-François Dartigues, Patrick Henry, Michel Lantéri-Minet, Christian Lucas, André Pradalier, Guy Chazot, Abdelkader El Hasnaoui.   

Abstract

OBJECTIVES: The objectives of this study were to determine the impact of headache on health-related quality of life in a nationwide sample of the French general population using a disease-specific measure, the Qualité de Vie et Migraine (QVM), to compare quality of life in subjects reporting different headache to types, and to evaluate the relationship between quality of life and severity, frequency, associated disability, and treatment responsiveness of headaches.
METHODS: The QVM questionnaire was included within a large epidemiological survey of 1486 headache sufferers. Diagnosis was assigned retrospectively using an algorithm based on the International Headache Society classification. Headache severity was assessed with the MIGSEV scale and disability with the MIDAS scale.
RESULTS: The mean global QVM score in the sample was 80.2. Quality of life was poorer in subjects with chronic daily headache (QVM score: 66.2) than in those with migraine (QVM score: 76.7), while those with other forms of episodic headache had the best quality of life (QVM score: 91.7). Quality-of-life scores were correlated with frequency, severity, disability, and treatment resistance of headaches (P <.001).
CONCLUSION: The QVM scale is a sensitive tool to measure health-related quality of life in headache sufferers in the general population.

Entities:  

Mesh:

Year:  2004        PMID: 15186301     DOI: 10.1111/j.1526-4610.2004.446005.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  12 in total

Review 1.  Burden of tension-type headache.

Authors:  Marc E Lenaerts
Journal:  Curr Pain Headache Rep       Date:  2006-12

2.  Adverse reactions related to drugs for headache treatment: clinical impact.

Authors:  Anna Ferrari; Alessandra Ottani; Alfio Bertolini; Arrigo Francesco Giuseppe Cicero; Ciro Pio Rosario Coccia; Sheila Leone; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

Review 3.  Outcome of Chronic Daily Headache or Chronic Migraine.

Authors:  Soo-Jin Cho; Tae-Jin Song; Min Kyung Chu
Journal:  Curr Pain Headache Rep       Date:  2016-01

Review 4.  Assessment and management of disability in chronic daily headache.

Authors:  William Pryse-Phillips
Journal:  Curr Pain Headache Rep       Date:  2005-02

Review 5.  Impact of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andrée
Journal:  J Headache Pain       Date:  2008-04-17       Impact factor: 7.277

6.  Impaired functioning and quality of life in severe migraine: the role of catastrophizing and associated symptoms.

Authors:  K A Holroyd; J B Drew; C K Cottrell; K M Romanek; V Heh
Journal:  Cephalalgia       Date:  2007-09-04       Impact factor: 6.292

7.  The relationship between alexithymia and headache impact: the role of somatization and pain catastrophizing.

Authors:  Eun-Jung Shim; Aram Park; Sung-Pa Park
Journal:  Qual Life Res       Date:  2018-06-04       Impact factor: 4.147

Review 8.  [Tools for assessing patient perception of the impact of migraine].

Authors:  Abdelkader El Hasnaoui; Adam Doble; Anne-Françoise Gaudin
Journal:  CNS Drugs       Date:  2006       Impact factor: 6.497

9.  The psychometric properties of the persian migraine-specific quality of life questionnaire version 2.1 in episodic and chronic migraines.

Authors:  Alireza Zandifar; Samaneh Sadat Masjedi; Faraidoon Haghdoost; Fatemeh Asgari; Navid Manouchehri; Mahboobeh Banihashemi; Mohammad Reza Najafi; Abbas Ghorbani; Behzad Zolfaghari; Ali Gholamrezaei; Vahid Shaygannejad; Mohammad Saadatnia
Journal:  ScientificWorldJournal       Date:  2013-08-27

10.  Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.

Authors:  Antonio Santoro; Andrea Fontana; Anna M Miscio; Michele M Zarrelli; Massimiliano Copetti; Maurizio A Leone
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.